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Abstract. Quantitative polymerase chain reaction (qPCR) for Toxoplasma gondiimulticopy genes has emerged as a
promising strategy for sensitive detection of parasite DNA. qPCR can be performed from blood samples, which are
minimally invasive to collect. However, there is no consensus about what type of blood specimen yields the best
sensitivity. The development of a novel protocol for qPCRdetection of T. gondii using blood clot, involving an appropriate
DNA extraction method and the use of an internal amplification control to monitor the reaction is presented in the current
study. Assays directed to the B1 and REP529 genes were performed in spiked specimens of whole blood, guanidine–
ethylenediaminetetraacetic acid blood, and clot. The clot-based qPCRwas shown to be more sensitive when compared
with other types of specimens, detecting five and 0.05 T. gondii genomes, using B1 and REP529 targets, respectively.
Finally, a comparative analysis with samples from HIV patients with clinical suspicion of toxoplasmosis was performed,
demonstrating the detection of four positive suspected cases with clots compared with only one using guanidine–
ethylenediaminetetraacetic acid blood. The high analytical sensitivity and the cost-effective advantages offered by clot
supports this methodology as a good laboratory tool to monitor parasite burden.
INTRODUCTION
Toxoplasmosis is a zoonotic disease caused by Toxo-
plasma gondii, an obligate intracellular coccidian parasite that
infects humans and virtually all warm-blooded organisms,
including birds, livestock, and wild mammals.1,2 The distri-
butionofT. gondii is ubiquitousand thehuman interactionwith
this parasite is common; one-third of the human population
is believed to be infected.3,4
In most cases toxoplasmosis is asymptomatic, however, it
can cause serious and life-threading conditions in immuno-
compromised subjects.3,5 Toxoplasma encephalitis (TE) due
to reactivation of latent toxoplasmosis in HIV patients is the
most severe clinical manifestation seen in this group.6–8 In
addition, the vertical transmission of this parasite is the most
important among pathogenic protozoa in human pregnancy.9
Thismakes toxoplasmosis an important public health concern
and the reliability of precise detection of T. gondii is crucial for
opportune diagnosis and further treatment.
Traditional diagnosis of toxoplasmosis includes serological
tests. However, this kind of approach has low sensitivity be-
cause of reactivation of the infection is not always followed by
changes in antibody production, and correlation with neuro-
imaging is needed for accuratediagnosis.10–12 For this reason,
direct demonstration of the presence of parasite in tissues or
body fluids would be a breakthrough for the diagnosis of this
disease.
In recent decades, a wide arrange of DNA-based detection
assays have been developed for T. gondii detection. Among
these, amplification of parasite DNA by quantitative poly-
merase chain reaction (qPCR) was performed in different
specimens, including amniotic fluid, tissue samples, cere-
brospinal fluid, and blood.13–16 Based on the premise that the
sensitivity of qPCR is enhanced by the number of target se-
quences, the B1 gene (35 copies)17 and the 529-bp repeat
element (REP 529, more than 300 copies)18 have been ex-
tensively used as targets for PCR detection.16,19,20 Never-
theless, collection of some specimens, such as brain tissue or
cerebrospinal fluid, represent a risk and are not always easily
obtained. In this way, blood offers many advantages as a low-
invasive specimen and its usefulness in the diagnosis of
toxoplasmosis by qPCR have been widely reported.16,21
Detection of T. gondii by qPCR is usually performed with
DNA obtained from whole blood22–24 and some studies rec-
ommend mixing the fresh specimen with guanidine or ethyl-
enediaminetetraacetic acid (EDTA) to prolong the lifespan of
the sample before DNA isolation.22 However, the shipping of
this reagent is no longer allowed under the new International
Air Transport regulations.25 This is a great obstacle for sample
transportation and the development of efficient methods for
DNA extraction and therefore efficient qPCR protocols from
other blood specimens are needed.
Although there is no consensus about what kind of blood
specimen is optimal for qPCR analysis, blood clot offersmany
cost-effective advantages for the collection and transport
because this specimen does not require special containers for
storage. In addition, the usefulness of the clot in qPCR has
been previously reported in the diagnosis of Chagas disease
and invasive aspergillosis, showing increased sensitivitywhen
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compared with serum or other blood specimens.25,26 How-
ever, clot has not been previously tested in the diagnosis of
T. gondii and there is little information about the required pa-
rameters to maximize the recovery of parasite DNA from this
specimen.
In this study, a practical method for appropriate DNA iso-
lation from blood clot was developed for its use in qPCR
directed to T. gondii genes B1 and REP529. An internal am-
plification control (IAC) was used to monitor the reaction.
Spiked sampleswere used to confirm the increased sensitivity
of the clot-based qPCR compared with whole blood in EDTA
and guanidine–EDTA blood (GEB) specimens. In addition, this
strategy was applied in a comparative quantitative analysis
among blood samples of HIV patients with neurological
symptoms and clinical suspicion of toxoplasmosis. In sum-
mary, the technical usefulness of blood clot as a cost-effective
specimen to improve the sensitivity of qPCR aimed tomonitor
T. gondii burden was demonstrated.
Methodology. Ethical statement. Patient collection proto-
cols were approved by the institutional review boards of the
study hospitals and associated institutions: Hospital Regional
de Loreto, Iquitos, Peru; Hospital Nacional Dos de Mayo,
Lima, Peru; Asociación Benéfica Prisma, Lima, Peru; Uni-
versidad Peruana Cayetano Heredia, Lima, Peru; and Uni-
versity of North Carolina at Chapel Hill, Chapel Hill, NC. All
patients, or their health care proxy, provided written informed
consent for the collection of samples and subsequent analysis.
Cell culture for parasite stocks. Monkey kidney fibroblast
LLC-MK2 cells were cultured in Roswell Park Memorial In-
stitute medium supplemented with 2% fetal bovine serum,
ampicillin (1 μg/mL), and streptomycin (1 μg/mL) in a 25 cm2
blue vented-cap plastic flask incubated at 37C in 5% CO2
and 95%humidity. Once the cell confluencewas 70–80%,RH
strain T. gondii tachyzoites were added (in a supplemented
medium 100 mM sodium pyruvate, 15 g of L-glutamine and
500 g of essential amino acids) to the original cell culture. After
8–10days, cultureswere centrifuged andpelletswerewashed
and resuspended in 1 mL of phosphate buffer saline 1×. Fi-
nally, the stock was diluted and counted in a Neubauer
chamber until a desired load of 1 × 106 tachyzoites permLwas
obtained.
Spiked blood specimen preparation. Five healthy donors
between the ages of 20 and 30 years, seronegative to toxo-
plasmosis, and with no significant previous medical history
were recruited. Blood samples were collected in tubes with
EDTA and tubes without additives. Blood with EDTA was
preserved at −80C as whole blood. Blood with additives was
centrifuged at 1,000 g for 15 minutes, after which serum
was drawn off to obtain the clot. For GEB, blood within EDTA
tubes was mixed with guanidine in a proportion of 1:1. Each
type of sample from healthy donors was aliquoted in volumes
of 1 mL and spiked with 1 × 106 tachyzoites (Figure 1).
Study participants and clinical samples. A total of 20 pa-
tients more than the age of 18, with ability to provide informed
consent, who were previously diagnosed with HIV by two
separate tests and with clinical suspicion of toxoplasmosis
were recruited for this work. Ten individuals were recruited
from Hospital Regional de Loreto, Iquitos, Peru (IQ-HIV), and
10 from Hospital Nacional Dos de Mayo, Lima, Peru (TOX-
HIV). Participants from both locations were only included if
their CD4+ cells count was lower than 250 cells/mL and if they
had an onset of neurological symptoms within the last
6 months, or if they were examined by imaging and the di-
agnostic impressionwas associatedwith toxoplasmosis. This
information was extracted from participants’ charts and the
comments of the neuroimaging studies. Peripheral blood
was collected from each patient and clot and GEB specimens
were prepared for analysis following the methods described
previously.
Internal amplificationcontrol.Tomonitor thecourseofqPCR,a
linearizedplasmid containinga sequenceofArabidopsis thaliana
(Table 1) was used as heterologous IAC.27 Both spiked and
clinical specimens were co-extracted with 40 pg of IAC added
immediately before the DNA extraction.
DNA extraction. The specimens from both spiked and
clinical samples were processed individually using High
Pure PCR Template Preparation Kit (Roche Diagnostics
Corp., Indianapolis, IN) following the manufacturer’s in-
structions. For clot specimens we completed a preceding
homogenization step involving the addition of 300 μL gua-
nidine hydrochloride 6 M (Sigma-Aldrich). After mixing, the
sample was transferred to a Lysing Matrix H 2 mL tube (MP
Biomedicals, Santa Ana, CA) followed by an agitation
cycle in a FastPrep-24™ 5G machine (MP Biomedicals)
(5.5m/second–300) to ensure the clot disaggregation before
the treatment with proteinase K. The DNA from each kind of
sample was eluted with 100 μL of kit’s elution buffer,
quantified in NanoDrop™ (Thermo Fisher Scientific, Waltham,
MA) and stored at −20C. DNA obtained from spiked blood
specimens was serially diluted 10-fold with healthy donor DNA
solution to cover an expected range between 1 and 105 para-
sites for calibration curves.
FIGURE 1. Schematic representation of study design. GEB =
guanidine–EDTA blood; IAC = internal amplification control; qPCR =
quantitative polymerase chain reaction.
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Serial dilution assay. Tomore effectively assess the limits of
detection and analytical performance of qPCR assays, we
calculated theparasite loads in termsofT. gondiigenomesper
PCR tube (Tgg) following the criteria described by Sterkers
et al.28 We reported the percentage of positive reactions after
testing the qPCR protocol in five replicates for every spiked
blood specimen in equivalents of 5, 0.5, and 0.05 Tgg per
reaction.
Quantitative polymerase chain reaction detection of B1 and
REP529. To perform a qPCR assay, fluorescence resonance
energy transfer hybridization probes were used for genes B1
and REP529. Both the probes and primers sequences have
been previously tested for T. gondii diagnosis29 (Table 1). A
single qPCR included 10 μL Taqman® Universal PCR Master
Mix II 1× (Roche), 1.2μLof eachprimer (10μM), 0.4μLof probe
(0.25μM), 2.2μLofMiliQwater, and5μLofDNA (20–150ng/μL).
In addition, 0.3 μL of IAC primers (5 μM) and 0.3 μL of probe
(10 μM) were added. The amplification protocol involved two
initial stages at 50C and 95C for 10 minutes each and 40
cycles at 95C for 15 seconds followed by 60C for 1 minute
and was performed in a Light Cycler® (Applied Biosystems,
Foster City, CA). The threshold cycle or cycle of quantifi-
cation (Cq) obtained for each clinical sample was corre-
lated with the calibration curve.
Statistical analysis. The experiments were performed in
triplicates. For standard curve analysis, data were expressed
as arithmetic mean ± standard deviation. Linear regression
analysis was performed to test goodness of fit and Student’s
t-test was used to analyze the statistical significance of the
observed slopes. A P value of less than 0.05 was considered
statistically significant. All the tests were calculated using
Prism software (Graphpad®, San Diego, CA).
RESULTS
Comparison of analytical sensitivity of qPCR from
blood specimens. After the qPCR was performed, the
quantification cycle (Cq) was obtained from the standard
curves and the reportable range of B1 and REP529 between
clot, whole blood, andGEBwas compared. For this purpose,
DNA isolated from spiked blood specimens were used to
construct three independent standard curves ranging from
105 to 1 tachyzoites per mL. High linearity and adequate
slopes were observed in curves from all samples, in-
dependent of the target. Calculated efficiency from all curves
also showed high values (Table 2).
The Cq values obtained from the clot standard curve de-
tected the lowest parasite load when compared with the ones
from whole blood and GEB. Each dilution was evaluated in
triplicate and the standard deviation obtained was less than
1.3. Assays with B1 as target allowed for the detection of 10
parasites in clot as compared with 100 parasites in GEB and
whole blood. By contrast, qPCR using REP529 detected one
parasite in clot as compared with 10 parasites in whole blood
and GEB. Thus, there is a 10-fold increase in sensitivity when
using clot for either B1 or REP529 assays (Figure 2).
However, the elution volume during DNA isolation might
affect or overestimate the limits of detection of qPCR assay.
To address this, we additionally performed a group of assays
aimed to detect parasite load units in terms of 5, 0.5, and 0.05
Tgg. This choice allowed a straightforward comparison be-
tween specimens.
With B1 as the target, the clot-based qPCR detected 0.5
Tgg in 60% of replicates, whereas assays in GEB and whole
blood could only detect 5 Tgg properly. Again, when REP529
is used as target, the qPCR performed in clot detected the
lowest parasite load (0.05 Tgg) in all its replicates. By contrast,
qPCR in whole blood (0.5 Tgg, 40% positives) and GEB (0.5
Tgg, 20% positives) showed a lower sensitivity and reliability
(Table 3).
Detection of T. gondii in HIV patients’ blood samples. To
validate the standardized protocols, blood specimens from20
HIV patients were analyzed by qPCR. Considering the higher
sensitivity yielded using REP529, experiments in clinical
TABLE 2
Standard curve parameters from quantitative polymerase chain reaction assays performed for sample specimens
Specimen Target Slopes Intercept r2 Amplification efficiency* (%)
Clot B1 −3.449 42.59 0.975 94.95
REP529 −3.400 35.72 0.994 96.84
Whole blood B1 −3.259 39.33 0.994 102.64
REP529 −3.332 29.56 0.98 99.99
Guanidine–EDTA blood B1 −3.205 43.12 0.98 105.12
REP529 −3.105 37.89 0.99 109.92
* Amplification efficiency was calculated based on the slope of the standard curve according to the minimum information for publication of quantitative real-time PCR experiments (MIQE)
guidelines.34 In all the standard curves, the slope of the regression line is significantly different from zero (P < 0.0001).
TABLE 1
Primer sets and probe sequences used for the detection of B1 and REP529 by quantitative polymerase chain reaction in this work
Target Probe/primer Sequence
B1 Probe FAM/BHQ 59-CAA CAA CTG CTC TAG CG-39
Forward 59-GCA TTG CCC GTC CAA ACT-39
Reverse 59-AGA CTG TAC GGA ATG GAG ACG AA-39
REP529 Probe FAM/MGB 59-AGG AGA GAT ATC AGG ACT GTA-39
Forward 59-GCT CCT CCA GCC CGT CCA AAC T-39
Reverse 59-TCC TCA CCC TCG CCT TCA T-39
Probe VIC/MGB 59-AGC ATC TGT TCT TGA AGG T-39
Internal amplification control Forward 59-ACC GTC ATG GAA CAG CAC GTA-39
Reverse 59-CTC CCG CAA ACC CTA TAA AT-39
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samples were performed only using this target. For each
sample, only clot and GEB specimens were prepared simul-
taneously. Of the 20 patients, T. gondiiwas detected from clot
specimens in four cases with the symptomatology of toxo-
plasmosis. By contrast, only oneGEB samplewas found to be
positive (Table 4). These results reflect again, the highdetection
power of the clot samples over the other blood specimens.
Whole blood was not analyzed because it was impossible to
prepare immediately after collection.
DISCUSSION
The diagnosis of TE by PCR has been previously tested for
HIV patients in cerebrospinal fluid and using the B1 gene as
the target, showing a sensitivity of 83%.30 However, lumbar
puncture is an invasive procedure that could be contra-
indicated in some cases. Therefore, the design of new pro-
tocols based on less invasive biological specimen collection
represents a great opportunity to improve the power of DNA-
based approaches for the diagnosis of toxoplasmosis. In the
presentstudy,weaimed todesignanefficientprotocol todetect
T. gondii in blood clot by qPCR. Thus, the efficiency of distinct
sample specimens was assessed for its practical usefulness in
diagnosis. Two sets of primers and probes, directed to B1 and
REP529, were evaluated among the specimens.
After Cq analyses were performed, a better power of de-
tection for all blood specimens was demonstrated when
REP529 was used as the target (Table 5). The effect of copy
number in qPCR sensitivity has been discussed previously,
and indicates the usefulness of REP529 for the diagnosis of
toxoplasmosis based on its high copy number and high level
of conservation of nucleotide sequence between parasites
isolates and strains.16,18 Moreover, the heterogeneity of B1 is
well known and represents a great challenge for primer and
probe design.31 This fact may largely affect the amplification
power because some parasite strains may not share the nu-
cleotide sequences.
Although previous studies reported the low sensitivity of
qPCR test based on blood for the diagnosis of TE,32 the ap-
pearance of false negatives might be a consequence of the
low recovery of DNA in the sample, the presence of PCR in-
hibitors, or the effect of large quantities of human genomic
DNA competing with the parasite DNA. Therefore, the design
of an appropriate test should include protocols that account
for DNA-associated difficulties due to the nature of blood
specimens.
Our results indicated that clot specimens yield a better
sensitivity for qPCR when compared with whole blood and
GEB (Figure 2, Table 5). The usefulness of clot as a diagnostic
specimen has been discussed for Chagas disease where it
was found to have a higher sensitivity compared with buffy
coat and whole blood.25 This phenomenon may be a con-
sequence of parasite entrapment within the cellular portion
of the clot or the sedimentation of circulating parasites. In
addition, previous studies (H. Mayta, unpublished data)
have shown that the sensitivity of qPCR is improved when
the clot is treated with lysing matrices on a tissue ho-
mogenizer. These tools may allow a better lysis of the
clotted blood and the trapped parasites, leading to a larger
amount of DNA extraction. This observation is consistent
with other reports for the diagnosis of invasive aspergil-
losis, where mechanical pretreatment of the clot increased
DNA yield and improved the diagnostic sensitivity of the
qPCR test.26
FIGURE 2. Comparison of dynamic ranges between distinct blood specimens for qPCR detection for Toxoplasma gondii. Standard curves were
built withCqobtained from three replicates for eachdilution ofDNA isolated fromclot,whole blood, andguanidine–EDTAblood.Both targets,B1 (A)
and REP529 (B), were tested for each kind of sample.
TABLE 3
Performances of qPCR for each blood specimen in terms of genomes of Toxoplasma gondii per qPCR
Specimen Target
50 Tgg 0.5 Tgg 0.05 Tgg
Np/Total %P Np/Total %P Np/Total %P
Clot B1 5/5 * 3/5 60% 0/5 0%
REP529 5/5 * 5/5 * 5/5 *
Guanidine–EDTA blood B1 5/5 * 0/5 0% 0/5 0%
REP529 5/5 * 1/5 20% 0/5 0%
Whole blood B1 5/5 * 0/5 0% 0/5 0%
REP529 5/5 * 2/5 40% 0/5 0%
qPCR=quantitative polymerase chain reaction; Tgg=T. gondiigenomes.Quantitativepolymerase chain reaction for each targetwas tested in five independent replicates to assess the number of
positives from total (Np/Total) and the percentage of detection (%P). The parasite equivalents in Tgg were constructed considering 100 μL of elution volume during DNA extraction.
* 100% positive reactions.
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The diagnosis of toxoplasmosis is a difficult task and sev-
eral studies have reported poor sensitivities in conventional
PCR methods made from peripheral blood, probably as a
consequence of low parasite loads.33 These observations are
congruent with our results, where the Cq for positive samples
reached high values that reflect very low parasite load
(Table 4).
The protocol designed in our study highlights the power of
detection by clot as a reliable specimen for the diagnosis of
toxoplasma in immunocompromised patients. Finally, our
results corroborate previous studies on qPCR-based diag-
nosis of toxoplasmosis, supporting the use of this design for
an efficient detection of parasite burden in blood samples. The
analysis based on clot provides several advantages as a cost-
effective sample. Moreover, the high sensitivity of clot qPCR
suggests the widespread use of this type of specimen as a
powerful resource for T. gondii detection.
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TABLE 4
Quantitative polymerase chain reaction with blood samples from HIV patients with suspicion of toxoplasmosis using REP 529
Sample ID Clinical impression
Quantitative
polymerase
chain reaction Cq–clot Cq–GEB
HIV patients
IQ-004 Neurological syndromes. CD4+ cells/mL: 73. NEGATIVE – –
IQ-007 Neurological syndromes. CD4+ cells/mL: 195. POSITIVE 35.18 ± 0.21 –
IQ-008 Neurological syndromes. NEGATIVE – –
IQ-009 Neurological syndromes. CD4+ cells/mL: 30. NEGATIVE – –
IQ-010 Neurological syndromes. CD4+ cells/mL: 38. NEGATIVE – –
IQ-012 MRI: Inflammatory process related to infectious disease, toxoplasmosis.
Neurological syndromes. CD4+ cells/mL: 45
POSITIVE 34.83 ± 0.18 –
IQ-013 CT: Multiple granulomas, brain strokes, and toxoplasmosis. Neurological
syndromes. CD4+ cells/mL: 33.
NEGATIVE – –
IQ-014 Neurological syndromes. CD4+ cells/mL: 44 NEGATIVE – –
IQ-015 MRI: Brain strokes, toxoplasmosis. Neurological syndromes.
CD4+ cells/mL: 182.
NEGATIVE – –
IQ-023 MRI: Multiple granuloma, vasogenic cerebral oedema, and toxoplasmosis.
Neurological syndromes. CD4+ cells/mL: 97.
POSITIVE 32.59 ± 0.33 33.47 ± 0.51
TOX-02 Neurological syndromes. CD4+ cells/mL: 97. NEGATIVE –
TOX-03 Neurological syndromes. CD4+ cells/mL: 153. NEGATIVE – –
TOX-04 MRI: Toxoplasmosis and progressive multifocal leukoencephalopathy.
Neurological syndromes. CD4+ cells/mL: 13.
NEGATIVE – –
TOX-05 Neurological syndromes. CD4+ cells/mL: 82 NEGATIVE – –
TOX-06 Neurological syndromes. NEGATIVE – –
TOX-07 MRI:Multiple granuloma, cerebral oedema, and toxoplasmosis. Neurological
syndromes. CD4+ cells/mL: 138.
NEGATIVE – –
TOX-08 Neurological syndromes. NEGATIVE – –
TOX-09 MRI: Inflammatory process related to infectious disease and toxoplasmosis.
Neurological syndromes. CD4+ cells/mL: 45
NEGATIVE – –
TOX-10 MRI: Inflammatory process related to infectious disease, brain strokes,
and toxoplasmosis. Neurological syndromes. CD4+ cells/mL: 35.
POSITIVE 31.15 ± 0.37 –




H-01 Not significant. NEGATIVE – –
H-02 Not significant. NEGATIVE – –
H-03 Not significant. NEGATIVE – –
H-04 Not significant. NEGATIVE – –
H-05 Not significant. NEGATIVE – –
Cq = cycle of quantification; MRI = magnetic resonance imaging; CT = computed tomography scan.
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